TDOC · Teladoc Health
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $6.88
Note written ·
How this view changed
- · Rating raised from Low to Medium. Analyst action, 9 November 2026: Eight brokers including BofA ($11.50), Deutsche Bank ($11), J.P. Morgan ($10) and Oppenheimer ($10) raised Teladoc price targets after the Q3 beat, between 30 October 2026 and 9 November 2026.
Price against the kill line
27.9% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $6.88, on record since 11 November 2026. The shares are up 34.6% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $6.88, the 28 October 2026 close before the Q3 report, which would erase the entire post-report gain. A FY2026 free-cash-flow guidance cut below $135 million, or an equity-based refinancing of the 2027 notes, would also show the case failing.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 29 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 605
- Revenue, change on a year (%)
- −3.4
- Gross margin (%)
- 68.6
- Operating margin (%)
- −4.6
- Free cash flow, four quarters ($M)
- 262
- Net cash, cash less debt ($M)
- −148
- Enterprise value to sales (×)
- 0.7
- Free-cash-flow yield (%)
- 16.3
All filed numbers
What Teladoc Health reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 605 | −3.4 | 68.6 | −4.6 |
| first filed | 607 | −4.0 | 68.6 | −6.1 |
| first filed | 614 | −2.5 | 67.8 | −10.1 |
| first filed | 642 | +0.3 | 69.3 | −5.6 |
| first filed | 626 | −2.2 | 70.1 | −8.3 |
| first filed | 632 | −1.6 | 69.8 | −8.6 |
| Pre-tax income ($M) | −26.3 |
| Net income ($M) four quarters: −155 | −26.9 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +2.8 |
| Operating cash flow ($M) | 268 |
| Capital spending ($M) | 6.4 |
| Free cash flow ($M) | 262 |
| Cash and short-term investments ($M) | 850 |
| Debt ($M) convertible debt | 998 |
| Net cash, cash less debt ($M) | −148 |
| Deferred revenue ($M) −12.6% on a year | 71.1 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 231 |
| Inventory ($M) | 30.7 |
| Shareholders' equity ($M) | 1,295 |
| Market value ($M) | 1,604 |
| Enterprise value, market value plus net debt ($M) | 1,752 |
| Enterprise value to sales (×) | 0.7 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.2 |
| Free-cash-flow yield (%) | 16.3 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 17.6% of shares outstanding sold short, 8.2 days of average trading to cover, +6.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $732K |
| 12 monthsfrom | $0 | $2.7M |
The thesis
Teladoc Health's Q3 2026 beat and the fast growth of BetterHelp insurance revenue give the shares a modestly better than even chance of beating the S&P 500 over three months. The rating is Medium because the Q4 guide still calls for BetterHelp revenue to fall 18.5% to 31.5%. Two things settle the case: how the company refinances $1.0 billion of convertible notes due 1 June 2027, and whether the Q4 report shows BetterHelp's decline easing.
The shares closed at $8.69 on 12 November 2026, well above the last close before the report on 28 October 2026. Eight brokers raised price targets between 30 October 2026 and 9 November 2026, but most of the raises kept neutral ratings, and Argus downgraded the stock to Sell on 2 November 2026. At $8.69 the shares sit above the $8 targets from Wells Fargo and TD Cowen and below the $9 targets from UBS and Barclays, so the price already reflects the Q3 beat at about the value the neutral-rated brokers assign.
Bullish and bearish views on Teladoc Health, Inc.
The bull case on Teladoc Health, Inc. (TDOC), in brief: Q3 beat guidance on every line. The bear case: cash-pay BetterHelp is shrinking fast.
Bull case
- Q3 beat guidance on every line. Revenue was $605.1 million against a $569–609 million guide, and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, excluding items the company sets aside) was $79.4 million, up 14%, per the 28 October 2026 results release.
- Insurance revenue is now material. BetterHelp booked $32.1 million of insurance revenue in Q3, per TIKR on 29 October 2026. Fierce Healthcare reported 27,000 insurance sessions a week and a company target of a $200 million annualized insurance run rate by the end of 2027.
- Targets moved up sharply. BofA Securities raised its target to $11.50 from $10.50 and Deutsche Bank to $11 from $10 on 30 October 2026. Oppenheimer raised to $10 from $7 on 2 November 2026 with an Outperform rating, and J.P. Morgan moved to $10 on 30 October 2026.
- Full-year guidance holds a cash floor. FY2026 guidance issued on 28 October 2026 is revenue of $2,395–2,441 million, adjusted EBITDA of $277–303 million and free cash flow of $135–165 million.
- Liquidity covers most of the maturity. Cash was $849.9 million at 30 September 2026, and $297.2 million of the revolving credit facility was available, per the Q3 2026 Form 10-Q.
- Canadian contracts keep coming. Empire Life launched a men's health program on Teladoc Health Canada's Expert Medical Opinion Service on 10 November 2026, and company news on 12 November 2026 reported Teladoc Health Canada named a strategic innovation partner by NL Health Services.
Bear case
- Cash-pay BetterHelp is shrinking fast. Cash-pay revenue fell about 25% to roughly $174.5 million in Q3, per Fierce Healthcare and TIKR on 29 October 2026. Average paying users were 0.336 million, against 0.382 million a year earlier.
- Q4 guide is steeper than the year. BetterHelp Q4 revenue growth is guided at negative 31.5% to negative 18.5%, against negative 16.1% to negative 12.9% for FY2026, per the 28 October 2026 release.
- A $1.0 billion maturity is now current. The 1.25% convertible senior notes due 1 June 2027 are a current liability at 30 September 2026, and their principal exceeds cash on hand, per the Q3 10-Q. On the Q3 call the chief financial officer described repurchasing a large part of the notes with cash and new term debt, potentially before year-end, per the Motley Fool on 29 October 2026.
- Most raised targets carry neutral ratings. Wells Fargo raised to $8 from $6 on 5 November 2026 and TD Cowen to $8 on 9 November 2026. UBS moved to $9 from $6.50 and Barclays to $9 from $7, all with neutral ratings.
- Insiders sold into the rally. Carlos Nueno, President of International, sold 29,432 shares at $9.20 on 6 November 2026 under a Rule 10b5-1 plan, per an SEC Form 4 filed 9 November 2026.
- Nine-month cash flow trails last year. Free cash flow was $85.4 million for the first nine months of 2026, against $113.5 million a year earlier, per the Q3 report.
Price setup
The shares closed at $8.69 on 12 November 2026, 12.1% below the 52-week intraday high of $9.89 set on 16 July 2026. The post-report high close was $9.41 on 5 November 2026; the shares then closed at $8.77 on 6 November 2026 and between $8.94 and $8.98 from 9 November to 11 November 2026. The three-month gain is 27.6%, from a reference close of $6.81 on 14 August 2026.
The 50-day moving average was $6.71 and the 200-day moving average $6.60 as of 12 November 2026, both well below the last close. The 52-week closing low was $4.47 on 12 February 2026. The $9.89 high from July is the level the shares have not reclaimed; a close above it would put them at a one-year high. The last close before the Q3 report, on 28 October 2026, marks where the post-report gain would be fully erased.
No earnings date falls inside the next 30 days. The nearest dated event is 1 December 2026, when the 2027 notes become convertible at holders' option.
Catalysts ahead
- 1 December 2026: 1.25% convertible notes due 2027 become convertible at holders' option. With the shares far below the conversion price, the notes stay a $1.0 billion cash obligation, which keeps the refinancing at the center of the case.
- ~31 December 2026 (est.): Possible term-debt refinancing of the 2027 notes, which management described as potentially before year-end. The cost and form of new debt decide how much free cash flow stays with shareholders and whether dilution is involved.
- ~February 2027 (est.): Q4 2026 results. Tests BetterHelp revenue against the guided 18.5% to 31.5% decline and shows whether insurance revenue keeps growing from $32.1 million.
What would change the view
A daily close below $6.88, the 28 October 2026 close before the Q3 report, which would erase the entire post-report gain. A FY2026 free-cash-flow guidance cut below $135 million, or an equity-based refinancing of the 2027 notes, would also show the case failing.
The risks this note tracks, each with what would confirm it:
- BetterHelp's cash-pay decline outruns insurance growth, so segment revenue keeps shrinking. Confirmed by: Q4 2026 BetterHelp revenue at or below the negative 31.5% end of guidance, or insurance revenue below the Q3 level of $32.1 million.
- The 2027 note refinancing dilutes shareholders or raises interest costs. Confirmed by: an equity offering, a new convertible, or term debt priced at a coupon that forces a cut to free-cash-flow guidance.
- Cash generation no longer supports the case. Confirmed by: FY2026 free-cash-flow guidance cut below the $135 million lower bound set on 28 October 2026.
- Integrated Care, the larger segment, stops growing and can no longer offset BetterHelp. Confirmed by: Q4 2026 Integrated Care revenue below the year-earlier quarter, after 2% growth in Q3 2026.
What it trades with
Teladoc sits in the managed-care and health-services group with ARDT and LMRI. Its October–November move followed its own 28 October 2026 report and the analyst revisions that followed, so the group does not explain it. Until the 2027 notes are refinanced, the shares carry exposure to credit conditions: wider spreads or higher borrowing costs for lower-rated issuers would raise the cost of the term debt the company plans to raise, independent of the group.
The evidence, claim by claim (8)
- Q3 2026 revenue was $605.1 million, down 3% year over year; Integrated Care $398.5 million (+2%); BetterHelp $206.6 million (−13%); adjusted EBITDA $79.4 million (+14%). Teladoc Health Q3 2026 results release (Form 8-K exhibit 99.1) · as of
- BetterHelp insurance revenue was $32.1 million in Q3 2026; cash-pay revenue fell about 25% to roughly $174.5 million. TIKR and Fierce Healthcare coverage of the Q3 2026 report · as of
- Q4 2026 guidance: revenue $569-615 million, adjusted EBITDA $74-100 million, BetterHelp revenue growth of −31.5% to −18.5%. Teladoc Health Q3 2026 results release (Form 8-K exhibit 99.1) · as of
- FY2026 guidance: revenue $2,395-2,441 million, adjusted EBITDA $277-303 million, free cash flow $135-165 million. Teladoc Health Q3 2026 results release (Form 8-K exhibit 99.1) · as of
- $1.0 billion of 1.25% convertible notes due 1 June 2027 are a current liability, convertible from 1 December 2026; cash was $849.9 million and $297.2 million of the revolver was available. Teladoc Health Q3 2026 Form 10-Q · as of
- Price targets raised: BofA to $11.50, Deutsche Bank to $11, J.P. Morgan to $10 (Neutral), Oppenheimer to $10 from $7 (Outperform). Benzinga and fiscal.ai analyst-action reports · as of
- UBS and Barclays raised targets to $9, Wells Fargo and TD Cowen to $8, all with neutral ratings; Argus downgraded to Sell on 2 November 2026. Benzinga and fiscal.ai analyst-action reports · as of
- President of International Carlos Nueno sold 29,432 shares at $9.20 on 6 November 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 9 November 2026 · as of
Sources
- Teladoc Health, Inc. - Form 8-K - FY2026 · sec.gov
- Teladoc Health, Inc. - Form 10-Q - FY2026 · sec.gov
- Teladoc Soars 11% on Q3 Beat and Raised Outlook as "Insurance Revenue Exceeded Our Expectations" · tikr.com ·
- Teladoc Health beats Q3 expectations as BetterHelp insurance growth accelerates · fiercehealthcare.com
- Teladoc: 3 Key Takeaways for Long-Term Investors · fool.com ·
Related · shared themes
AGL
agilon health
agilon health roughly doubled its 2026 adjusted EBITDA guidance to $145–$155 million after a second profitable quarter, giving the shares a…
BTSG
BrightSpring Health Services
BrightSpring Health Services is growing profit faster than revenue, with third-quarter 2026 adjusted EBITDA up 42% on specialty pharmacy…
UNH
UnitedHealth Group
UnitedHealth Group's earnings recovery, with 2026 adjusted EPS guided to at least $20.50 and a buyback widened by 50 million shares, gives…
AMN
AMN Healthcare Services
AMN Healthcare Services is more likely to lag the S&P 500 because its fourth-quarter outlook cuts strike revenue to $5 million from $59…